172 related articles for article (PubMed ID: 8453188)
1. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
Harris MG; Coleman SG; Faulds D; Chrisp P
Drugs Aging; 1993; 3(1):9-25. PubMed ID: 8453188
[TBL] [Abstract][Full Text] [Related]
2. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
Kassouf W; Tanguay S; Aprikian AG
J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
[TBL] [Abstract][Full Text] [Related]
3. Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion.
Decensi A; Torrisi R; Marroni P; Pensa F; Padovani P; Boccardo F
Prostate; 1994; 24(1):17-23. PubMed ID: 8290386
[TBL] [Abstract][Full Text] [Related]
4. Nilutamide: an antiandrogen for the treatment of prostate cancer.
Dole EJ; Holdsworth MT
Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
[TBL] [Abstract][Full Text] [Related]
5. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review.
Du Plessis DJ
Urology; 1991; 37(2 Suppl):20-4. PubMed ID: 1992599
[TBL] [Abstract][Full Text] [Related]
6. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
[TBL] [Abstract][Full Text] [Related]
7. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
Janknegt RA; Abbou CC; Bartoletti R; Bernstein-Hahn L; Bracken B; Brisset JM; Da Silva FC; Chisholm G; Crawford ED; Debruyne FM
J Urol; 1993 Jan; 149(1):77-82; discussion 83. PubMed ID: 7678043
[TBL] [Abstract][Full Text] [Related]
8. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
[TBL] [Abstract][Full Text] [Related]
9. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
Decensi AU; Boccardo F; Guarneri D; Positano N; Paoletti MC; Costantini M; Martorana G; Giuliani L
J Urol; 1991 Aug; 146(2):377-81. PubMed ID: 1856935
[TBL] [Abstract][Full Text] [Related]
10. Nilutamide: possible utility as a second-line hormonal agent.
Desai A; Stadler WM; Vogelzang NJ
Urology; 2001 Dec; 58(6):1016-20. PubMed ID: 11744479
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
Mahler C; Verhelst J; Denis L
Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
[TBL] [Abstract][Full Text] [Related]
13. Effect of androgen deprivation therapy on local symptoms and tumour progression in men with metastatic carcinoma of the prostate.
Smith JA; Janknegt RA; Abbou CC; de Gery A
Eur Urol; 1997; 31 Suppl 3():25-9. PubMed ID: 9101212
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).
Bertagna C; De Géry A; Hucher M; François JP; Zanirato J
Br J Urol; 1994 Apr; 73(4):396-402. PubMed ID: 8199827
[TBL] [Abstract][Full Text] [Related]
15. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
16. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.
Janknegt RA
Cancer; 1993 Dec; 72(12 Suppl):3874-7. PubMed ID: 8252507
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group.
Dijkman GA; Janknegt RA; De Reijke TM; Debruyne FM
J Urol; 1997 Jul; 158(1):160-3. PubMed ID: 9186345
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer.
Migliari R; Scarpa RM; Campus G; De Lisa A; Zucca I; D'Atri M; Serra A; Usai E
Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):147-53. PubMed ID: 1830407
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of nilutamide.
Gaillard-Moguilewsky M; de Gery A; Ulmann A
Cancer; 1993 Dec; 72(12 Suppl):3828-9. PubMed ID: 8252498
[No Abstract] [Full Text] [Related]
20. Nilutamide pneumonitis: a report on eight patients.
Pfitzenmeyer P; Foucher P; Piard F; Coudert B; Braud ML; Gabez P; Lacroix S; Mabille JP; Camus P
Thorax; 1992 Aug; 47(8):622-7. PubMed ID: 1412120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
